摘要
冠心病已成为中国重大的公共卫生问题,通过分析肠道菌群及代谢产物实现冠心病的辅助诊断、治疗及预防靶点逐渐成为研究热点,多个研究表明肠道菌群紊乱可能通过直接作用或其代谢产物间接介导冠心病进程,而一些肠道益生菌则具有抑制动脉粥样硬化的作用。该文对肠道菌群及其代谢产物的变化在冠心病中的作用机制及其作为生物标志物的诊断效能研究现状进行了综述,以期为临床应用提供新思路。
Coronary heart disease(CHD)has become a major public health issue in China.Gut microbiota has gradually become a CHD research hotspot in terms of auxiliary diagnosis,treatment and prevention targets.Results from multiple studies have shown that gut microbiota dysbiosis may mediate the process of CHD directly or indirectly through their metabolites,and some intestinal probiotics could inhibit the progression of atherosclerosis.The research advances on the related mechanism and their diagnostic efficacy as biomarkers of gut microbiota and metabolites in CHD are reviewed here to provide a reference for current and future clinical application.
作者
徐秋月
段勇
Xu Qiuyue;Duan Yong(Department of Clinical Laboratory,the First Affiliated Hospital of Kunming Medical University、Yunnan Key Laboratory of Laboratory Medicine、Yunnan Province Clinical Research Center for Laboratory Medicine,Kunming 650032,China)
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2023年第7期748-753,共6页
Chinese Journal of Laboratory Medicine
作者简介
通信作者:段勇,Email:duanyong7@139.com。
